Approved HIV Drugs
Approved HIV Drugs
IAS 2013: Acute Retroviral Syndrome Linked to HIV Disease Progression
- Details
- Category: HIV Treatment
- Published on Thursday, 01 August 2013 00:00
- Written by Liz Highleyman
People who reported higher scores on a scale of symptom severity during initial HIV infection had lower CD4 T-cell counts, higher viral load set-points, and greater likelihood of HIV disease progression than those with mild or no acute antiretroviral symptoms, researchers reported at the recent 7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2013) in Kuala Lumpur.
IAS 2013: Cost of HIV Drugs in Resource-limited Settings [VIDEO]
- Details
- Category: HIV Treatment
- Published on Thursday, 01 August 2013 00:00
- Written by Gregory Fowler
The price of first- and second-line antiretroviral medications has fallen in recent years, largely due to increased competition among generic drug producers, but the newest antiretrovirals continue to be priced out of reach of many who need them, according to a report released by Médecins Sans Frontières/Doctors Without Borders to coincide with the recent 7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2013) in Kuala Lumpur.
IAS 2013: Second-line Therapy in Resource-limited Settings [VIDEO]
- Details
- Category: HIV Treatment
- Published on Monday, 08 July 2013 00:00
- Written by Gregory Fowler
A second-line regimen of a protease inhibitor plus either 2 NRTIs or raltegravir (Isentress) led to good outcomes for people with HIV in Africa after initial regimen failure, according to a study presented at the 7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2013) in Kuala Lumpur.
IAS 2013: Stribild 'Quad' Pill Continues to Show Good Efficacy at 96 Weeks
- Details
- Category: HIV Treatment
- Published on Thursday, 01 August 2013 00:00
- Written by Liz Highleyman
The 4-in-1 Stribild single-tablet regimen maintains HIV viral load suppression through 96 weeks and remains generally well-tolerated, researchers reported at the recent 7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2013) this month in Kuala Lumpur. Another study found that Stribild and its component cobicistat appear safe for people with mild-to-moderate kidney impairment.
IAS 2013: Lower-dose Efavirenz as Effective as Standard Dose [VIDEO]
- Details
- Category: HIV Treatment
- Published on Monday, 08 July 2013 00:00
- Written by Gregory Fowler
Lowering the dosage of efavirenz (Sustiva) from 600 mg to 400 mg did not compromise its effectiveness, according to data from the ENCORE1 study presented at the 7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2013) this week in Kuala Lumpur.
More Articles...
- HIV Treatment Highlights from IAS 2013 [VIDEO]
- IAS 2013: Switch to Etravirine Maintains Viral Suppression and Improves Lipid Levels
- IAS 2013: First-line Antiretroviral Therapy has Improved Over Time, Meta-analysis Shows
- IAS 2013: Study Supports WHO Second-line HIV Treatment Guidelines for Resource-limited Countries
Web Design and Development by